Long-term Study of Asenapine in Participants With Residual Subtype, Receiving Multiple or/and High Dose Drugs, or Treatment Refractory Schizophrenia (P06238)

Inclusion Criteria: * Minimum age of 20 years * Participants who meet at least one of the following: * current diagnosis of schizophrenia of residual subtype * received treatment with 3 or more antipsychotic drugs * treatment-refractory participants with schizophrenia * 65 years old and over with positive schizophrenia symptoms with score of 3 (mild) or more in 1 or more items in the positive subscale of the Positive and Negative Syndrome Scale (PANSS) at the baseline * Participants who have a Clinical Global Impressions-Severity (CGI-S) score of at least 4 (moderately ill) at the baseline Exclusion Criteria: * Uncontrolled, unstable clinically significant medical condition * Clinically significant abnormal laboratory, vital sign, physical examination, or electrocardiogram (ECG) findings at Screening * Positive pregnancy test at Screening, or the intention to become pregnant during the course of the study * Seizure disorder beyond childhood (12 years old or younger) * History of neuroleptic malignant syndrome * Allergy or sensitivity to drugs such as psychotropics and antipsychotics * Known history of or currently treated for narrow angle glaucoma * Parkinson's disease * Diagnosis of schizoaffective disorder; schizophreniform disorder * Concurrent psychiatric disorder other than schizophrenia coded on Axis I; a primary diagnosis other than schizophrenia * Diagnosis of borderline personality disorder * Diagnosis of mental retardation or organic brain disorder * Cur…